Assertio Holdings Appoints New Chief Medical Officer

TL;DR

Assertio Holdings brings in Dr. Diamond from Horizon Therapeutics as new CMO.

AI Summary

Assertio Holdings, Inc. announced on May 16, 2024, the appointment of Dr. Robert L. Diamond as Chief Medical Officer and Executive Vice President. Dr. Diamond previously served as Chief Medical Officer at Horizon Therapeutics plc. This appointment is part of the company's ongoing efforts to strengthen its leadership team.

Why It Matters

The appointment of a new Chief Medical Officer can signal a strategic shift in the company's research and development focus or its approach to clinical trials and regulatory affairs.

Risk Assessment

Risk Level: low — The filing details a routine executive appointment, which typically carries low inherent risk.

Key Players & Entities

• Assertio Holdings, Inc. (company) — Registrant
• Dr. Robert L. Diamond (person) — Appointed Chief Medical Officer and Executive Vice President
• Horizon Therapeutics plc (company) — Previous employer of Dr. Diamond
• May 16, 2024 (date) — Date of the earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ge on which registered: Common Stock, $0.0001 par value ASRT The Nasdaq Stock Mar
• $850,000 — tter, Mr. O'Grady's base salary will be $850,000, with an annual target cash bonus oppor
• $5,000 — of outplacement services, not to exceed $5,000 per month and (vi) 100% of Mr. O'Grady'

Filing Documents

• tm2415496d2_8k.htm (8-K) — 36KB
• tm2415496d2_ex99-1.htm (EX-99.1) — 11KB
• tm2415496d2_ex99-1img002.jpg (GRAPHIC) — 6KB
• 0001104659-24-065886.txt ( ) — 232KB
• asrt-20240516.xsd (EX-101.SCH) — 3KB
• asrt-20240516_lab.xml (EX-101.LAB) — 33KB
• asrt-20240516_pre.xml (EX-101.PRE) — 22KB
• tm2415496d2_8k_htm.xml (XML) — 4KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Executive Officer Transition Effective May 29, 2024, the Board of Directors (the "Board") of Assertio Holdings, Inc. (the "Company") appointed Brendan P. O'Grady to serve as the Company's Chief Executive Officer (and principal executive officer) and as a director. Heather L. Mason, who has served as Interim Chief Executive Officer since January 2024, will transition back to her role as independent director. Mr. O'Grady, age 57, most recently served as CEO of the Global Formulations Business at Glenmark Pharmaceuticals Ltd. (India: NSE), a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell (NYSE: AMWL), an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from 2001 to 2021, most recently serving as CEO and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, and the abbreviated new drug application drug distribution business. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi (Nasdaq: SNY) from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York and an M.B.A. from Baker University. On May

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On May 29, 2024, the Company issued a press release announcing Mr. O'Grady's appointment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release, dated May 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASSERTIO HOLDINGS, INC. Date: May 29, 2024 By: /s/ Sam Schlessinger Sam Schlessinger Senior Vice President, General Counsel